Elimination of the Mound-Building Termite, Nasutitermes exitiosus (Isoptera: Termitidae) in South-Eastern Australia Using Bistrifluron Bait.

Bistrifluron, a benzoylphenylurea compound, was evaluated for efficacy against Nasutitermes exitiosus (Hill), a mound-building species in southern Australia. Bistrifluron bait (trade name Xterm) was delivered as containerized pellets inserted into plastic feeding stations implanted in the sides of mounds-60 g for bistrifluron bait-treated mounds and 120 g of blank bait for untreated mounds. Termites actively tunneled in the gaps between pellets and removed bait from the canisters. All five treated mounds were eventually eliminated, and all five untreated mounds remained active at the end of the trial. Four of the five treated mounds were considered dead and excavated after 26 wk, but there were earlier signs of mound distress-reduced repair of experimental casement damage and reduced activity in bait canisters by 22 wk and reduced internal mound temperature after 11 wk. One treated mound showed activity in the bait station right through until almost the end of the trial (47 wk), but excavation at 49 wk showed no further activity in the mound. The five untreated colonies removed on average 97% of blank bait offered, while the five treated colonies removed on average 39.1% of bait offered. There was a wide variation in temperature profiles of mounds (up to 15°C for both minimum and maximum internal temperatures), from the beginning of the trial and even before the effects of baiting were evident.

Residual treatment of Aedes aegypti (Diptera: Culicidae) in containers using pyriproxyfen slow-release granules (Sumilarv 0.5G).

The residual efficacy of pyriproxyfen against Aedes aegypti (L.) was examined by treating 2-liter buckets with a range of rates of Sumilarv 0.5G (100, 10, 1, and 0.1 mg product/liter or nominal dose of 500, 50, 5, and 0.5 ppb active ingredient) under semifield conditions. Approximately every 2 wk, pupal emergence inhibition (EI) was measured by using Cairns colony Ae. aegypti. Pooled water samples from the five replicate buckets were analyzed for active pyriproxyfen by using ultra-high-pressure liquid chromatography with tandem mass spectrometry detection. A strong dose-response in EI was exhibited, with the 0.1 mg/liter giving approximately 50% EI for only the initial week, whereas the 10 and 100 mg/liter doses produced EI > 90% for 8 and 40 wk, respectively. Measurable levels of active ingredient were detected in the 100, 10, and 1 mg/liter treatments, with measured starting concentrations of just 1-2-1.4% of the delivered (active ingredient) dose. Pyriproxyfen was detected in the 100 mg/liter treatment through the entire course of the trial (60 wk).

Geographic distribution suggests that Solenopsis invicta is the host of predilection for Solenopsis invicta virus 1.

Solenopsis invicta virus 1 (SINV-1) was found regularly and prevalently in S. invicta. In sampled locations where S. invicta and S. geminata are sympatric (specifically, Gainesville, FL and Travis, TX), SINV-1 was detected in S. geminata. Conversely, in areas in which S. geminata and S. invicta are allopatric, SINV-1 was not detected in S. geminata; these locations included north Australia (n=12), southern Mexico (n=107), Hawaii (n=48), Taiwan (n=12), and the Johnston Atoll (n=6). A similar relationship was observed for S. richteri. In areas in which S. invicta and S. richteri were sympatric, SINV-1 was detected in the S. richteri population, but in areas in which S. invicta and S. richteri were allopatric, SINV-1 was not detected. These occurrences suggest that S. invicta is the host of predilection, or preferred host for SINV-1, and that the congenerics, S. geminata and S. richteri serve as either accidental, reservoir, or transfer hosts. The minus genome strand of SINV-1 was detected in S. geminata and S. richteri indicating that these species may serve as functional hosts capable of supporting SINV-1 replication. SINV-1 was not detected in S. xyloni regardless of its proximity to S. invicta. These results suggest that SINV-1 may be an example of pathogen spillover or pollution.

Field evaluations of the efficacy of Distance Plus on invasive ant species in northern Australia.

The efficacy of Distance Plus Ant Bait, containing the insect growth regulator pyriproxyfen, was tested in the field against two invasive ant species in northern Australia: African big-headed ant (Pheidole megacephala (F.)) and yellow crazy ant (Anoplolepis gracilipes (Fr. Smith)). Results were also gained for a third pest species, Singapore ant (Monomorium destructor (Jerdon)), from one trial focused primarily on P. megacephala. Five studies were conducted throughout northern Australia, each with different protocols, but common to all was the broad-scale dispersal of Distance Plus, coupled with long-term monitoring of ant population levels. Additionally, a laboratory trial was conducted to assess if there was a direct toxic effect by the bait on A. gracilipes workers, and ant community data were collected at some sites in the A. gracilipes trial to assess nontarget impacts and subsequent ecological recovery. All three species were greatly affected by the treatments. The abundance of P. megacephala declined dramatically in all trials, and by the final assessment for each study, very few ants remained, with those remaining being attributable to edge effects from neighboring untreated properties. At both sites that it occurred, M. destructor was initially at least codominant with P. megacephala, but by the final assessment, only three M. destructor individuals were present at one lure at one site, and only a single individual at the other site. Abundance of A. gracilipes fell, on average, to 31% of control levels by 91 d and then slowly recovered, with subsequent treatments only providing slightly greater control. No direct toxic effect on workers was found in the laboratory trial, indicating that population declines of A. gracilipes were typical bait-related declines resulting from reduced worker replacement. Nontarget impacts of the bait could not be distinguished from the negative competitive impacts ofA. gracilipes, but there was a noticeable absence of some key common ant species posttreatment, which was more likely the result of baiting rather than competitive exclusion. The species composition of treated and untreated sites was statistically indistinguishable in multivariate analysis within 2 yr posttreatment, indicating ecological recovery. Our findings indicate that Distance Plus has great potential for invasive ant management.

Pyriproxyfen for the control of Australian salt-marsh mosquito, Aedes vigilax.

The efficacy of pyriproxyfen against the Australian salt-marsh mosquito, Aedes vigilax, was examined in 2 laboratory and 1 semi-field study using both technical grade and formulated products. In a dose-response study, the median emergence inhibition (EI50) and EI95 values were determined to be 0.019 and 0.076 ppb, respectively, for pyriproxyfen technical grade, 0.021 and 0.092 ppb for a microencapsulated formulation (Sumilarv 90CS), and 0.054 and 0.236 ppb for the formulated s-methoprene product, Altosid Liquid Larvicide. A further laboratory comparison of the microencapsulated formulation of pyriproxyfen and Altosid, at the nominal field rate for Altosid, showed that both products provided 100% emergence inhibition and this was confirmed in a semi-field study, which also included a granular formulation of pyriproxyfen (Sumilarv 0.5G).

Elimination of Coptotermes lacteus (Froggatt) (Blattodea: Rhinotemitidae) Colonies Using Bistrifluron Bait Applied through In-Ground Bait Stations Surrounding Mounds.

The efficacy of bistrifluron termite bait was evaluated using in-ground bait stations placed around Coptotermes lacteus mounds in south-eastern Australia during late summer and autumn (late February to late May 2012). Four in-ground bait stations containing timber billets were placed around each of twenty mounds. Once sufficient numbers of in-ground stations were infested by termites, mounds were assigned to one of four groups (one, two, three or four 120 g bait canisters or 120 to 480 g bait in total per mound) and bait canisters installed. One mound, nominally assigned treatment with two canisters ultimately had no termite interception in any of the four in-ground stations and not treated. Eighteen of the remaining 19 colonies were eliminated by 12 weeks after bait placement, irrespective of bait quantity removed (range 43 to 480 g). Measures of colony decline-mound repair capability and internal core temperature-did not accurately reflect the colony decline, as untreated colonies showed a similar pattern of decline in both repair capability and internal mound core temperature. However, during the ensuing spring-summer period, capacity to repair the mound was restored in untreated colonies and the internal core temperature profile was similar to the previous spring-summer period which indicated that these untreated colonies remained healthy.

Efficacy of Bistrifluron Termite Bait on Coptotermes lacteus (Isoptera: Rhinotermitidae) in Southern Australia.

Bistrifluron, a benzoylphenyl urea compound, was evaluated for efficacy against Coptotermes lacteus (Froggatt), a mound-building species in southern Australia. Bistrifluron bait (tradename Xterm) was delivered as containerized pellets inserted into plastic in-ground feeding stations implanted in the sides of mounds. Termites actively tunneled in the gaps between pellets and removed bait from the canisters. Two separate trials were conducted, one commencing on 22 September 2011 and the second commencing on 30 November 2011. In trial 1, all 13 treated colonies (seven single and six double treatments) were eliminated within 19 wk, while all five untreated colonies remained healthy. In trial 2, all four treated colonies were eliminated within 14 wk. In trial 1, bait consumed or removed in treated mounds averaged 105 g for single treatments and 147 g for dual treatments, and overall ranged from 7 to 309 g (70-3,090 mg bistrifluron). In trial 2, the four treated colonies removed an average of 85 g of bait. At the time mounds were dismantled, all showed signs of inattention: external cracking, delamination, and general external weathering. Mound repair and temperature profile data indicate that colony decline commenced much earlier than 19 wk and 14 wk, respectively, for trials 1 and 2, from as early as 4 wk onward. The ability of colonies to repair mound damage was impaired as early as 4 wk in some colonies, and mean internal mound temperatures in treated mounds began declining from 8 wk onward and clearly diverged from mean temperatures of untreated mounds thereafter.

Kink shape solutions of the Maxwell-Lorentz system.

In the limit of high amplitude oscillating electromagnetic fields, a sequence of kink antikink shaped optical waves has been found in the Maxwell's equations coupled to a single Lorentz oscillator and with Kerr nonlinearity. The individual kinks and antikinks result from a traveling wave assumption and their stability has been assessed by numerical simulations. For typical physical parameter values the kink width is of the order of tens of femtoseconds.

Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study.

INTRODUCTION: The effects of angiotensin converting enzyme inhibitor on systemic right ventricular size and function are unknown. METHODS: Prospective, double blind, randomized, placebo-controlled clinical trial of 1-year therapy with Ramipril in adult patients with DTGA status postatrial baffle procedure. Primary endpoints were change in systemic right ventricular ejection fraction (RVEF) and right ventricular size assessed by magnetic resonance imaging (MRI). RESULTS: Seventeen patients were enrolled into the study. Mean age at study enrollment was 26.4+/-5.2 years. Mean baseline RVEF was 44+/-6.5%, mean RVEDV was 206.3+/-75.5 ml. Eight patients were randomized to the treatment group and 9 patients were randomized to the placebo group. RVEF did not improve in the Ramipril group from baseline to 1 year (43.8+/-7.1% vs. 40.9+/-13.3%, p=0.52) and remain unchanged in the placebo group (44.3+/-6.3 vs. 46.3+/-9.6%, p=0.42). RVEDV (184.5+/-56.4 ml vs. 179.6+/-66.4 ml, p=0.64) and RVESV (109.5+/-19.4 ml vs. 111.8+/-30.1, p=0.74) remained unchanged in the Ramipril group from baseline to 1 year as well as in the placebo group (228.1+/-89.2 ml vs. 204.5+/-50.4 ml, p=0.42 and 117.5+/-36.9 ml vs. 117.4+/-26.2 ml, p=0.99, respectively). CONCLUSION: One-year treatment with Ramipril does not seem to affect right ventricular function or size in adult patients with systemic right ventricles after a Mustard or Senning procedure. CONDENSED ABSTRACT: 17 Adult patients (mean age of 26.4 +/- 5.2 years) with systemic right ventricles were blindly randomized to 1-year treatment with Ramipril placebo. Systemic right ventricular function (RVEF) and size (RVEDV) were assessed by magnetic resonance imaging at baseline and 1 year. RVEF failed to improve in the Ramipril group (43.8+/-7.1% vs. 40.9+/-13.3%, p=0.52) and remain unchanged in the placebo group (44.3+/-6.3 vs. 46.3+/-9.6%, p=0.42). RVEDV remained unchanged in the study group (184.5+/-56.4 ml vs. 179.6+/-66.4 ml, p=0.64 as well as in the placebo group (228.1 +/- 89.2 ml vs. 204.5 +/- 50.4 ml, p = 0.42). One-year treatment with Ramipril does not improve right ventricular function or attenuate remodeling in adult patients with systemic right ventricles.